{"denoms":[{"counts":[{"groupId":"BG000","value":"283"},{"groupId":"BG001","value":"286"},{"groupId":"BG002","value":"569"}],"units":"Participants"}],"groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"BG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"BG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.84","value":"64.3"},{"groupId":"BG001","spread":"9.03","value":"64.4"},{"groupId":"BG002","spread":"8.93","value":"64.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"232"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"173"},{"groupId":"BG002","value":"337"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"22"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"34"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"17"}]}],"title":"Denmark"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"57"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"18"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"19"}]}],"title":"Greece"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"39"}]}],"title":"Israel"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"36"}]}],"title":"Japan"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"40"}]}],"title":"Korea, Republic of"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"28"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"48"}]}],"title":"Russian Federation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"51"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"31"}]}],"title":"Sweden"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"20"}]}],"title":"Taiwan, Province of China"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"51"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"36"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"277"}],"title":"I"},{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"179"}],"title":"II"},{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"113"}],"title":"III"}]}],"description":"The International Staging System (ISS) consists of following 3 stages - Stage I: serum beta2-microglobulin less than (\\<) 3.5 milligram per liter (mg/L) and albumin greater than or equal to (\\>=) 3.5 gram per 100 milliliter (g/100 ml); Stage II: neither stage I nor stage III and Stage III: serum beta2-microglobulin \\>= 5.5 mg/L.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage of Disease (ISS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"295"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"165"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"76"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"33"}],"title":">3"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"No. of Prior Lines of Therapy","unitOfMeasure":"Participants"}]}